An Over-the-Counter (OTC) monograph is a set of regulations\nestablished by the U.S. Food and Drug Administration (FDA) for non-prescription\ndrugs. These monographs provide a comprehensive framework for the ingredients,\nlabeling, and therapeutic uses of a specific category of OTC drugs. The\nmonograph system streamlines the process for manufacturers to develop and\nmarket safe and effective OTC products without requiring approvals.<\/p>\n\n\n\n
The FDA categorizes OTC drugs<\/a> into various\ntherapeutic classes (e.g., antacids, cough and cold products, pain relief,\nsunscreens) based on their intended use and active ingredients.<\/p>\n\n\n\n For each therapeutic class, the FDA develops a monograph\nthat outlines the active ingredients, their permitted concentrations, labeling\nrequirements, dosing instructions, and any other relevant specifications. The\nmonograph serves as a standard for products within that category.<\/p>\n\n\n\n The monograph also specifies which active ingredients are\ngenerally recognized as safe and effective (GRASE) for treating specific\nconditions.<\/p>\n\n\n\n The monograph sets labeling requirements, with drug facts\nwhich includes use, warnings, and other information that must be included on\nthe product’s packaging. It may also outline testing requirements to ensure\nproduct quality and consistency.<\/p>\n\n\n\n Manufacturers looking to create an OTC product within a\nspecific therapeutic class must formulate their product according to the\nmonograph’s specifications. If the product adheres to the monograph’s\nrequirements, it can be marketed without requiring individual FDA approval.<\/p>\n\n\n\n The FDA periodically reviews and updates OTC monographs to\nreflect new scientific information, safety concerns, and changes in industry\nstandards. Manufacturers are required to adjust their products to comply with\nupdated monograph requirements.<\/p>\n\n\n\n In some cases where a manufacturer wishes to market an OTC\nproduct with an ingredient or use that is not covered by an existing monograph,\nthey can pursue an OTC New Drug Application (NDA) or a New Dietary Ingredient\n(NDI) Notification, depending on the nature of the product.<\/p>\n\n\n\n It’s important for manufacturers to carefully follow the\nmonograph guidelines when developing and marketing OTC drugs to ensure\ncompliance with FDA regulations.<\/p>\n\n\n\n OTC drug manufacturers are required to comply with FDA drug\nregulations which includes\nestablishment registration<\/a>, drug listing, label compliance and cGMP regulations.<\/p>\n\n\n\n Liberty Management Group<\/a> , as a leading FDA consultant with provide assistance \u00a0with drug establishment registration<\/a>, drug listing and label review<\/a>.<\/p>\n\n\n\n Sudha S<\/p>\n\n\n\n Regulatory Consultant<\/p>\n\n\n\n Email : Office@libertymanagement.us<\/p>\n\n\n\n www.fdahelp.us<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" An Over-the-Counter (OTC) monograph is a set of regulations established by the U.S. Food and Drug Administration (FDA) for non-prescription drugs. These monographs provide a comprehensive framework for the ingredients, labeling, and therapeutic uses of a specific category of OTC drugs. The monograph system streamlines the process for manufacturers to develop and market safe and … Continue reading “OTC MONOGRAPH”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-199","post","type-post","status-publish","format-standard","hentry","category-fda-registration-drug"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/comments?post=199"}],"version-history":[{"count":1,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/199\/revisions"}],"predecessor-version":[{"id":200,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/199\/revisions\/200"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/media?parent=199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/categories?post=199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/tags?post=199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}